Sesen Bio to Present at the Jefferies Virtual Healthcare Conference
May 26 2020 - 7:00AM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced it will be featured as a
presenting company at the Jefferies Virtual Healthcare Conference
on Tuesday, June 2, 2020.
Event: Jefferies Virtual Healthcare Conference Date: June 2,
2020 Time: 8:30 - 8:55 AM ET
A live webcast of the Company’s presentation will be accessible
from the Investors & Media section of Sesen Bio’s website,
www.sesenbio.com. An archived replay of the webcast will be
available on the Company's website for 90 days after the
conference.
About Sesen Bio Sesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the
treatment of patients with cancer. The Company’s lead program,
Vicinium, also known as VB4-845, is currently in the follow-up
stage of a Phase 3 registration trial for the treatment of
high-risk, BCG-unresponsive non-muscle invasive bladder cancer
(NMIBC). In December 2019, the Company initiated the BLA submission
for Vicinium to the FDA under Rolling Review. Vicinium is a locally
administered targeted fusion protein composed of an anti-EpCAM
antibody fragment tethered to a truncated form of Pseudomonas
Exotoxin A for the treatment of high-risk NMIBC. For more
information, please visit the company’s website at
www.sesenbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200526005065/en/
Erin Clark, Vice President, Corporate Strategy & Investor
Relations ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024